Patients with systemic sclerosis-associated pulmonary arterial hypertension who were given combination sequential therapy had improved survival rates compared with patients receiving upfront combination or monotherapy.
Investigators examined the prevalence, characteristics, treatment, and outcomes for patients with pulmonary hypertension in a systemic-sclerosis-associated interstitial lung disease cohort.
Investigators examined right ventricular function and pulmonary arterial compliance at rest and during exercise in patients with systemic sclerosis with normal or mildly elevated mean pulmonary artery pressures, or with manifest pulmonary hypertension.
Researchers used optical coherence tomography angiography to measure retinal microvascular blood flow in patients with systemic sclerosis with no clinical signs of retinal involvement.
Lung‐epithelial‐derived surfactant protein has been identified as a biomarker of systemic sclerosis-interstitial lung disease.
Mark Pimentel, MD, discusses the release of a new blood test that may aid in the diagnosis of scleroderma and systemic sclerosis.
Systemic sclerosis-associated pulmonary hypertension and systemic sclerosis-associated interstitial lung disease exhibit similar but distinct gene expression profiles.
Severe gastrointestinal disease is common in early systemic sclerosis, and is linked to increased mortality.
Researchers estimated the incidence and prevalence of systemic sclerosis in recent years in the United Kingdom.
Factors associated with a higher risk for mortality included male sex, exercise desaturation, and diffusing capacity of the lungs for carbon monoxide <50%.
